JP2013126979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013126979A5 JP2013126979A5 JP2012273427A JP2012273427A JP2013126979A5 JP 2013126979 A5 JP2013126979 A5 JP 2013126979A5 JP 2012273427 A JP2012273427 A JP 2012273427A JP 2012273427 A JP2012273427 A JP 2012273427A JP 2013126979 A5 JP2013126979 A5 JP 2013126979A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- temsirolimus
- pharmaceutical composition
- inotuzumab ozogamicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 25
- 229960000235 temsirolimus Drugs 0.000 claims 25
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 25
- 229950004101 inotuzumab ozogamicin Drugs 0.000 claims 23
- 201000011510 cancer Diseases 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 15
- 239000003937 drug carrier Substances 0.000 claims 15
- 230000001093 anti-cancer Effects 0.000 claims 14
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 13
- 239000003085 diluting agent Substances 0.000 claims 13
- 206010009944 Colon cancer Diseases 0.000 claims 9
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 7
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 6
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 208000029742 colonic neoplasm Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 5
- 206010017758 gastric cancer Diseases 0.000 claims 5
- 201000011549 stomach cancer Diseases 0.000 claims 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 206010000830 Acute leukaemia Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010005949 Bone cancer Diseases 0.000 claims 3
- 208000018084 Bone neoplasm Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006143 Brain stem glioma Diseases 0.000 claims 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 206010061252 Intraocular melanoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 3
- 206010061336 Pelvic neoplasm Diseases 0.000 claims 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims 3
- 206010034299 Penile cancer Diseases 0.000 claims 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 3
- 206010046392 Ureteric cancer Diseases 0.000 claims 3
- 206010046431 Urethral cancer Diseases 0.000 claims 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 201000005969 Uveal melanoma Diseases 0.000 claims 3
- 206010047741 Vulval cancer Diseases 0.000 claims 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 3
- 201000011165 anus cancer Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000024207 chronic leukemia Diseases 0.000 claims 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 230000003325 follicular Effects 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000002575 ocular melanoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000003708 skin melanoma Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 201000002314 small intestine cancer Diseases 0.000 claims 3
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 206010046885 vaginal cancer Diseases 0.000 claims 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims 3
- 201000005102 vulva cancer Diseases 0.000 claims 3
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576831P | 2011-12-16 | 2011-12-16 | |
| US61/576,831 | 2011-12-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013126979A JP2013126979A (ja) | 2013-06-27 |
| JP2013126979A5 true JP2013126979A5 (enExample) | 2016-02-04 |
Family
ID=47557418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012273427A Pending JP2013126979A (ja) | 2011-12-16 | 2012-12-14 | 癌の処置のためのイノツズマブオゾガマイシンおよびトーリセルの組合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9642918B2 (enExample) |
| EP (1) | EP2790723A1 (enExample) |
| JP (1) | JP2013126979A (enExample) |
| KR (2) | KR20140107413A (enExample) |
| CN (1) | CN104023747A (enExample) |
| AU (2) | AU2012351728A1 (enExample) |
| BR (1) | BR112014014181A2 (enExample) |
| CA (1) | CA2859089A1 (enExample) |
| HK (1) | HK1201191A1 (enExample) |
| IL (1) | IL233165A0 (enExample) |
| MX (1) | MX2014007077A (enExample) |
| RU (1) | RU2607594C2 (enExample) |
| WO (1) | WO2013088304A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015065954A1 (en) | 2013-11-04 | 2015-05-07 | Pfizer, Inc. | Anti-efna4 antibody-drug conjugates |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| JP2018517744A (ja) * | 2015-06-15 | 2018-07-05 | ニューサウス イノベーションズ プロプライアタリー リミティド | 有機アルセノキシド化合物とｍＴＯＲ阻害剤の組合せ医薬 |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CA3024723A1 (en) | 2016-05-20 | 2017-11-23 | Robert B. Dubridge | Single domain serum albumin binding protein |
| BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
| JP2020524262A (ja) | 2017-06-06 | 2020-08-13 | ザ・ジョンズ・ホプキンス・ユニバーシティ | エピジェネティック療法による合成致死性の誘導 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| JP7084990B2 (ja) | 2017-10-13 | 2022-06-15 | ハープーン セラピューティクス，インク． | 三重特異性タンパク質と使用方法 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| CA3127142A1 (en) * | 2019-02-13 | 2020-08-20 | Coimmune, Inc. | Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| JP2022551909A (ja) * | 2019-10-10 | 2022-12-14 | ブライオロジクス インコーポレイテッド | ブリオスタチンによる腫瘍関連抗原の誘導方法 |
| US20250262293A1 (en) | 2020-07-07 | 2025-08-21 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| MX2024000674A (es) | 2021-07-13 | 2024-02-07 | BioNTech SE | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US4667637A (en) | 1986-01-08 | 1987-05-26 | Brunswick Corporation | Gated knock detector for internal-combustion engines |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| WO2007124252A2 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| WO2007125252A1 (fr) | 2006-04-26 | 2007-11-08 | France Telecom | Procede et systeme de gestion d'un paiement electronique |
| GB0609378D0 (en) * | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| EP2358390A1 (en) * | 2008-11-13 | 2011-08-24 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic combination therapies and uses thereof |
| US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
| SG181834A1 (en) * | 2009-12-21 | 2012-07-30 | Genentech Inc | Antibody formulation |
| EP2563391B1 (en) * | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
-
2012
- 2012-12-04 BR BR112014014181A patent/BR112014014181A2/pt not_active IP Right Cessation
- 2012-12-04 WO PCT/IB2012/056958 patent/WO2013088304A1/en not_active Ceased
- 2012-12-04 MX MX2014007077A patent/MX2014007077A/es unknown
- 2012-12-04 AU AU2012351728A patent/AU2012351728A1/en not_active Abandoned
- 2012-12-04 KR KR1020147018997A patent/KR20140107413A/ko not_active Ceased
- 2012-12-04 RU RU2014124005A patent/RU2607594C2/ru not_active IP Right Cessation
- 2012-12-04 CA CA2859089A patent/CA2859089A1/en not_active Abandoned
- 2012-12-04 HK HK15101740.4A patent/HK1201191A1/xx unknown
- 2012-12-04 KR KR1020177011120A patent/KR20170049617A/ko not_active Ceased
- 2012-12-04 US US14/365,793 patent/US9642918B2/en not_active Expired - Fee Related
- 2012-12-04 CN CN201280062130.7A patent/CN104023747A/zh active Pending
- 2012-12-04 EP EP12813985.4A patent/EP2790723A1/en not_active Ceased
- 2012-12-14 JP JP2012273427A patent/JP2013126979A/ja active Pending
-
2014
- 2014-06-16 IL IL233165A patent/IL233165A0/en unknown
-
2016
- 2016-04-26 AU AU2016202621A patent/AU2016202621B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013126979A5 (enExample) | ||
| RU2014124005A (ru) | Комбинация инотузумаба озогамицина и торизела для лечения рака | |
| JP2014512356A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| CA2898771C (en) | Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament | |
| KR102418766B1 (ko) | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 | |
| JP2014509659A5 (enExample) | ||
| JP2016536352A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2016502504A5 (enExample) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| RU2013120311A (ru) | Терапевтическое применение агониста tlr и комбинированная терапия | |
| JP2007530526A5 (enExample) | ||
| JP2006503919A5 (enExample) | ||
| WO2016204193A1 (ja) | 抗がん剤 | |
| JP2015524847A (ja) | 小細胞肺がんを治療するためのベンゾジアゼピン | |
| CN102665711A (zh) | 青蒿素基药物与其他化学治疗剂的抗癌组合物 | |
| RU2007126978A (ru) | Комбинации терапевтических агентов для лечения рака | |
| JP2016522202A5 (enExample) | ||
| JP2003533485A5 (enExample) | ||
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 |